The price of Xiidra (lifitegrast) eye drops can vary depending on insurance coverage, pharmacy, and geographic location. Without insurance, a 30-day supply can cost around $400 to $500. For individuals with commercial insurance, out-of-pocket costs may be lower, often ranging from $10 to $75 per month, especially with manufacturer savings programs.
How much does Xiidra cost with different insurance plans?
Coverage and co-pays for Xiidra differ significantly between insurance providers. Many insurance plans include Xiidra on their formulary, but specific co-pay amounts can range widely. Patients are advised to check with their individual insurance provider for precise details on their coverage and out-of-pocket expenses.
Are there any savings programs for Xiidra?
Yes, manufacturer savings programs are available for eligible commercially insured patients. These programs can help reduce the monthly cost of Xiidra. Information about these savings programs can typically be found on the Xiidra manufacturer's website.
What is the difference between Xiidra and Restasis?
Both Xiidra and Restasis are prescription eye drops used to treat the signs and symptoms of dry eye disease. However, they work through different mechanisms. Xiidra contains lifitegrast, a lymphocyte function-associated antigen-1 (LFA-1) antagonist, which works by blocking T-cell activation and the release of inflammatory cytokines. Restasis contains cyclosporine, which is an immunomodulator that helps increase tear production. Pricing and insurance coverage for Restasis also vary.
When does Xiidra's patent expire?
The patent landscape for Xiidra is complex. While original patents exist, there have been patent challenges and exclusivities. For detailed and up-to-date information on Xiidra's patent status and expiry dates, DrugPatentWatch.com is a valuable resource [1].
Where can I buy Xiidra?
Xiidra is available by prescription only and can be obtained from most retail pharmacies. Your doctor will send the prescription directly to your preferred pharmacy.
Sources:
1. https://drugpatentwatch.com/